Compare AbCellera Biologics Inc (ABCL) vs Uber Technologies Inc (UBER) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Uber Technologies Inc — how do they compare? AbCellera Biologics Inc trades at $7.2 (market cap $2.35B), while Uber Technologies Inc trades at $72.94 (market cap $151.31B). The key difference: Uber Technologies Inc is far larger — about 64.4× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Uber Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | UBER | |
|---|---|---|
Market Cap | $2.35B | $151.31B |
Sector | Health | Industrials |
52-Week High | $8.12 | $100.10 |
52-Week Low | $2.78 | $68.61 |
Enterprise Value | $1.99B | $157.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Uber (UBER) trades at $72.42, down 2.7% today, amid a bearish technical signal but strong fundamentals. The stock shows robust revenue growth, with 2025 revenue reaching $52.02 billion, and a net income margin of 15.91%. Recent news highlights strategic moves into autonomous vehicles, including robotaxi pilots in Madrid and Munich, while cost-cutting measures like HR layoffs aim to improve efficiency.
The outlook is mixed: analyst consensus is strongly bullish with a $109.25 price target, but technical indicators and projected 2026 cash flow decline pose risks. Key opportunities include expansion in autonomous driving partnerships; risks involve competitive pressures and execution challenges in new markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
